Physician profile
Tabitha Moorehead
NPI 1346974144
$1,648.09
in general payments reported to CMS, 2019-2025
12 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $130 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Travel and Lodging: $674 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.14 |
| Travel and Lodging | $673.95 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,204.09 | 2025 | |
| Abiomed | $122.86 | 2025 | |
| Novo Nordisk INC | $58.89 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Impulse Dynamics (USA) INC. | $54.52 | 2025 | Optimizer |
| Teva Pharmaceuticals USA, INC. | $52.96 | 2024-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $29.02 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.78 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $24.78 | 2025 | Verquvo |
| Phathom Pharmaceuticals, INC. | $18.95 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $18.33 | 2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $18.10 | 2024 | |
| Teleflex LLC | $16.81 | 2025 | Guideliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Moorehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.